• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

    9/17/24 11:22:47 AM ET
    $AZN
    $BLTE
    $HCM
    $IH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies.

    There is no fee for participants to log in, attend live presentations and/or ask questions.

    Pre-registration is suggested. Please register here: www.adr.db.com/dbvic

    September 24 Agenda (US Eastern Standard Time):

    • 8:00 AM: First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • 8:30 AM: Lotus Technology Inc (NASDAQ:LOT)
    • 9:00 AM: HUTCHMED (China) Limited ((AIM: HCM, NASDAQ:HCM, and HKEX:13))
    • 9:30 AM: iHuman Inc. (NYSE:IH)
    • 10:00 AM: Marks and Spencer ((LSE: MKS, OTC:MAKSY)
    • 10:30 AM: SSE plc ((LSE: SSE, OTC:SSEZY)
    • 11:00 AM: BDO Unibank, Inc ((PSE: BDO, OTC:BDOUY)
    • 11:30 AM: AstraZeneca plc ((LSE: AZN, NASDAQ:AZN)

    September 25 Agenda (US Eastern Standard Time):

    • 8:00 AM: Yiren Digital Ltd (NYSE:YRD)
    • 8:30 AM: KPN ((Euronext Amsterdam: KPN, OTC:KKPNY)
    • 9:00 AM: Viomi Technology Co., Ltd (NASDAQ:VIOT)
    • 9:30 AM: Carrefour S.A. (PARIS:CA, OTC:CRRFY)
    • 10:00 AM: EDP Group ((Euronext Lisbon: EDP, OTC:EDPFY)
    • 10:30 AM: Repsol S.A ((BMAD: REP, OTC:REPYY)
    • 11:00 AM: Belite Bio, Inc  (NASDAQ:BLTE)
    • 11:30 AM: DSM-Firmenich AG ((DSFIR:AEX, OTC:DSFIY)

    The presentations will be available for replay after the Conference.

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    For further information, please contact:

    Dylan Riddle

    Deutsche Bank AG

    Press & Media Relations

    Tel. +12122504982

    Cell. +1(904)3866481

    Email [email protected]

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© September 2024 Deutsche Bank AG. All rights reserved.



    Primary Logo

    Get the next $AZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZN
    $BLTE
    $HCM
    $IH

    CompanyDatePrice TargetRatingAnalyst
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    11/20/2024Sell → Neutral
    UBS
    AstraZeneca PLC
    $AZN
    11/6/2024Sell → Hold
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    9/13/2024Hold → Sell
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    5/30/2024$97.00Buy
    Goldman
    More analyst ratings

    $AZN
    $BLTE
    $HCM
    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HUTCHMED downgraded by HSBC Securities

      HSBC Securities downgraded HUTCHMED from Buy to Hold

      5/13/25 3:20:36 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      6/2/25 1:13:01 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      6/2/25 1:03:35 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      6/2/25 6:03:30 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Leadership Updates

    Live Leadership Updates

    See more
    • Lotus Technology Announces Management and Board Changes

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today announced changes to its management team and board of directors. The board of directors of the company (the "Board") has approved the appointment of Mr. Daxue Wang as the Chief Financial Officer ("CFO") of the Company effective April 8, 2025. Mr. Wang is a seasoned executive across corporate and prominent financial institutions, most recently serving as CFO of Radar Auto. Prior to that, Mr. Wang held several executive positions in Zhejiang Kangsheng, Huzhou Moshan Asset Management, Morgan Stanley Securities, ICBC Credi

      4/8/25 4:30:00 PM ET
      $LOT
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

      3/5/25 5:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viomi Technology Co., Ltd Appoints New President of Operations to Promote High-quality Business Development

      GUANGZHOU, China, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of Mr. Guang Wu as President of Operations, effective December 4, 2024. In this role, Mr. Wu will focus on driving high-quality business development and enhancing operational efficiency. Mr. Wu brings over 20 years of experience in business development and marketing within the domestic home appliances and home furnishing industry. Prior to joining Viomi, he served as Vice President and General Manager of Domestic Marketing at Sleemon Group. Before that, he managed domestic m

      12/4/24 4:00:00 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary

    $AZN
    $BLTE
    $HCM
    $IH
    Financials

    Live finance-specific insights

    See more
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Lotus Technology Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

      Over 12,000 vehicles delivered in 2024, a year-on-year increase over 70%.Total revenue reached $924 million, a 36% year-on-year growth.Achieved a reduction in operating expenses for five consecutive quarters through rigorous execution of efficiency enhancement initiatives.The Company is expected to consolidate the entire global business of the Lotus brand by acquisition of a majority interest in Lotus UK upon the closing of Geely's put option. NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus Tech" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today announced its unaudited financial results for the fourth quarter and th

      4/22/25 7:00:00 AM ET
      $LOT

    $AZN
    $BLTE
    $HCM
    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial

      Daiichi Sankyo and AstraZeneca's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes in the first-line setting for a broad population of patients with HER2 positive metastatic breast cancer Positive results from the DESTINY-Breast09 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to taxane, trastuzumab and pertuzumab (THP) as a first-line treatment in patients with HER2 positive metastatic breast cancer. Results will be

      6/2/25 8:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

      AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes in the 1st-line setting for a broad population of patients with HER2-positive metastatic breast cancer Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer. Results

      6/2/25 8:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

      — The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the data presented — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) announces primary results from the interim analysis of the SACHI Phase III study. These results were presented in a late-breaking oral presentation on Sunday, June 1, 2025, during the American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, USA. SACHI is a Phas

      6/1/25 8:00:00 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

      SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

      11/12/24 6:35:53 AM ET
      $VIOT
      Consumer Electronics/Appliances
      Consumer Discretionary
    • SEC Form SC 13G filed by Lotus Technology Inc.

      SC 13G - Lotus Technology Inc. (0001962746) (Subject)

      11/12/24 6:07:58 AM ET
      $LOT
    • SEC Form SC 13G filed by Lotus Technology Inc.

      SC 13G - Lotus Technology Inc. (0001962746) (Subject)

      11/8/24 6:04:35 AM ET
      $LOT